expect another failure, page-8

whilst i am no longer optimistic i think that the comment 'that lack of tolerence needs to be incorporated into efficacy as a failure in terms of efficacy' is not a death knell.
titus pullo's observation that treatment may be restricted to responders gives some hope.
it appears despite some faults in the phase 3 study that those whom completed course had a positive response to bronchitol.
as i recollect second phase 3 study was a response to fda concerns concerning first phase 3 study.
no observation at that time that first phase 3 study flawed as lack of tolerence needed to be incorporated into efficacy as a failure in terms of efficacy.